title: The Effect of Formulation Excipients and Thermal Treatment on the Release Properties of Lisinopril Spheres and Tablets.
abstract: Multiparticulate systems are used in the development of controlled release systems. The objective of this study was to determine the effect of the wax level, the type of excipient, and the exposure of the tablets to thermal treatment on drug release. Spheres from multiparticulate system with different wax levels and excipients were developed using the drug Lisinopril and compressed into tablets; these tablets were analyzed to determine the drug release. All tablets contained constant level of Lisinopril (10% w/w) and Compritol (30% and 50% w/w). Also, as a diluent, all of them contained 30% w/w Avicel and 30% w/w dibasic calcium phosphate or lactose, or 60% Avicel. Tablets compacted from spheres prepared by extruder/marumerizer and using 30% w/w lipid and 60% Avicel released 84% of drug at six hours of dissolution testing, while tablets of the same composition but prepared using 30% dibasic calcium phosphate and 30% Avicel released 101%. When the tablets were thermally treated, the drug release reduced. As the percent of lipid increased in the formulation, the drug release decreased. Compaction of tablets prepared from spheres with wax has potential for controlling the drug release.
authors.affiliation: School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, P.O. Box 365067, San Juan, PR 00936-5067, USA.
authors.forename: Zoriely
authors.initials: Z
authors.lastname: Amador Ríos
authors.affiliation: School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, P.O. Box 365067, San Juan, PR 00936-5067, USA.
authors.forename: Evone Shehata
authors.initials: ES
authors.lastname: Ghaly
mesh_terms: D000284:Administration, Oral; D000327:Adsorption; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000737:chemistry; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations / Q000737:chemistry*; D004339:Drug Compounding; D005079:Excipients / Q000737:chemistry*; D006358:Hot Temperature; D007700:Kinetics; D017706:Lisinopril / Q000008:administration & dosage* / Q000737:chemistry*; D008422:Materials Testing; D013607:Tablets; D014885:Waxes / Q000737:chemistry*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002214:Capsules; D003692:Delayed-Action Preparations; D005079:Excipients; D013607:Tablets; D014885:Waxes; D017706:Lisinopril